Navellier & Associates Inc. Has $2.07 Million Stock Holdings in Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Navellier & Associates Inc. cut its stake in Horizon Therapeutics Public Limited (NASDAQ:HZNPGet Rating) by 2.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,916 shares of the biopharmaceutical company’s stock after selling 699 shares during the period. Navellier & Associates Inc.’s holdings in Horizon Therapeutics Public were worth $2,067,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Valley National Advisers Inc. increased its stake in shares of Horizon Therapeutics Public by 21.2% in the 1st quarter. Valley National Advisers Inc. now owns 801 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 140 shares during the last quarter. Lebenthal Global Advisors LLC increased its stake in shares of Horizon Therapeutics Public by 5.8% in the 2nd quarter. Lebenthal Global Advisors LLC now owns 2,669 shares of the biopharmaceutical company’s stock valued at $212,000 after purchasing an additional 147 shares during the last quarter. Arizona State Retirement System increased its stake in shares of Horizon Therapeutics Public by 0.3% in the 2nd quarter. Arizona State Retirement System now owns 60,139 shares of the biopharmaceutical company’s stock valued at $4,797,000 after purchasing an additional 158 shares during the last quarter. Aspire Private Capital LLC grew its position in Horizon Therapeutics Public by 2.3% during the 2nd quarter. Aspire Private Capital LLC now owns 7,082 shares of the biopharmaceutical company’s stock worth $565,000 after acquiring an additional 158 shares during the last quarter. Finally, US Bancorp DE grew its position in Horizon Therapeutics Public by 0.4% during the 1st quarter. US Bancorp DE now owns 44,359 shares of the biopharmaceutical company’s stock worth $4,667,000 after acquiring an additional 179 shares during the last quarter. Institutional investors own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

HZNP has been the topic of a number of research reports. The Goldman Sachs Group reduced their price objective on Horizon Therapeutics Public from $164.00 to $144.00 and set a “buy” rating on the stock in a research report on Thursday, August 4th. Piper Sandler reduced their price objective on Horizon Therapeutics Public from $90.00 to $88.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 25th. HC Wainwright initiated coverage on Horizon Therapeutics Public in a research report on Tuesday, November 1st. They set a “neutral” rating and a $74.00 price objective on the stock. BMO Capital Markets reduced their price objective on Horizon Therapeutics Public from $145.00 to $117.00 and set an “outperform” rating on the stock in a research report on Thursday, August 4th. Finally, StockNews.com upgraded Horizon Therapeutics Public from a “hold” rating to a “buy” rating in a research report on Thursday, November 3rd. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $105.00.

Horizon Therapeutics Public Trading Up 0.3 %

Shares of NASDAQ HZNP traded up $0.26 during trading on Thursday, reaching $77.53. The company had a trading volume of 1,297,155 shares, compared to its average volume of 2,766,304. The company’s fifty day moving average price is $67.51 and its 200-day moving average price is $74.32. Horizon Therapeutics Public Limited has a 12 month low of $57.84 and a 12 month high of $117.49. The stock has a market cap of $17.57 billion, a P/E ratio of 31.77, a PEG ratio of 1.54 and a beta of 1.09. The company has a quick ratio of 3.74, a current ratio of 3.96 and a debt-to-equity ratio of 0.51.

Horizon Therapeutics Public Profile

(Get Rating)

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation.

Further Reading

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.